Abbott Laboratories (ABT) shares soared 5.28% in pre-market trading on Wednesday after the healthcare giant reported better-than-expected first-quarter earnings and reaffirmed its full-year 2025 guidance.
The company posted adjusted earnings per share of $1.09, surpassing analysts' estimates of $1.07. Abbott's strong performance was driven by robust growth in its medical devices segment, particularly in diabetes care, where sales of continuous glucose monitors increased 18.3% year-over-year. The nutrition segment also showed solid growth, with global sales rising 3.8% on a reported basis.
Despite ongoing global economic uncertainties, Abbott maintained its full-year 2025 guidance, projecting adjusted earnings per share of $5.05 to $5.25 and organic sales growth of 7.5% to 8.5%. The company's ability to navigate through challenging market conditions while delivering strong results across its diversified portfolio has boosted investor confidence, contributing to the significant pre-market stock surge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.